SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the Company) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
“ Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML “ “ Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 “ “ Positive...
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
“ Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML “ “ Registration-directed trial of ziftomenib in NPM1-mutant AML on track to...
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the Company) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome First patient dosed in KOMET-008...
KOMET-008 is evaluating ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC in patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged AML SAN DIEGO, Feb. 26, 2024 (GLOBE...